Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsMary Murray, MD, FACOG
Clinical InstructorAbout
Research
Publications
2026
Utilization of Tumor Markers for Intraoperative Specimen Radiography Does Not Decrease the Rate of Margin Positivity in Breast Conservation Surgery (BCS)
Prasad R, Brainerd M, Ortega C, Gabra J, Mangira C, Brett-Morris A, Mamone C, Fenton A, Murray M. Utilization of Tumor Markers for Intraoperative Specimen Radiography Does Not Decrease the Rate of Margin Positivity in Breast Conservation Surgery (BCS). The American Surgeon 2026, 92: 2539-2545. PMID: 42080622, DOI: 10.1177/00031348261448903.Peer-Reviewed Original ResearchIdentifying Disparities in Timely Receipt of Radiation After Breast‐Conserving Surgery
Reyes N, Ortega C, Mendiola A, Murray M, Fenton A, Brett-Morris A, Mangira C. Identifying Disparities in Timely Receipt of Radiation After Breast‐Conserving Surgery. The Breast Journal 2026, 2026: 9942451. PMID: 41641173, PMCID: PMC12865119, DOI: 10.1155/tbj/9942451.Peer-Reviewed Original Research
2025
Axillary Surgical Management in Breast Cancer Patients after Neoadjuvant Systemic Therapy: A Delphi Study
Stanczyk M, ElSherif A, Cheung T, Fanning A, Mendiola A, Fenton A, Pratt D, Murray M, Valente S, Al-Hilli Z, Lang J. Axillary Surgical Management in Breast Cancer Patients after Neoadjuvant Systemic Therapy: A Delphi Study. Breast Care 2025, 20: 338-347. PMID: 40584028, PMCID: PMC12201954, DOI: 10.1159/000546267.Peer-Reviewed Original Research
2022
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer
Pellicane J, Beitsch P, Rock D, Budway R, Dul C, Kelemen P, Ashikari A, Baron P, Weinstein P, Mislowsky A, Lee L, Beatty J, Murray M, Dupree B, Finn C, Corcoran K, Wang S, Menicucci A, Yoder E, Blumencranz L, Dauer P, Audeh W, Whitworth P, Group N. Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer. Surgical Oncology 2022, 45: 101885. PMID: 36436423, DOI: 10.1016/j.suronc.2022.101885.Peer-Reviewed Original ResearchGenomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
Whitworth P, Beitsch P, Murray M, Richards P, Mislowsky A, Dul C, Pellicane J, Baron P, Rahman R, Lee L, Dupree B, Kelemen P, Ashikari A, Budway R, Lopez-Penalver C, Dooley W, Wang S, Dauer P, Menicucci A, Yoder E, Finn C, Blumencranz L, Audeh W. Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy. JCO Precision Oncology 2022, 6: e2200197. PMID: 36108259, PMCID: PMC9489196, DOI: 10.1200/po.22.00197.Peer-Reviewed Original ResearchOmission of Radiation in Conservative Treatment for Breast Cancer: Opportunity for De-escalation of Care
Hong MJ, Lum SS, Dupont E, Howard-McNatt M, Chiba A, Levine EA, Gass JS, Gallagher K, Fenton A, Murray M, Solomon NL, Ollila DW, Lazar M, Namm JP, Walters LL, Chagpar AB, Investigators S. Omission of Radiation in Conservative Treatment for Breast Cancer: Opportunity for De-escalation of Care. Journal Of Surgical Research 2022, 279: 393-397. PMID: 35835032, DOI: 10.1016/j.jss.2022.06.036.Peer-Reviewed Original ResearchDistinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, Murray M, Gittleman M, Budway R, Rahman R, Kelemen P, Dooley W, Rock D, Cowan K, Lesnikoski B, Barone J, Ashikari A, Dupree B, Wang S, Menicucci A, Yoder E, Finn C, Corcoran K, Blumencranz L, Audeh W. Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature. JCO Precision Oncology 2022, 6: e2100463. PMID: 35476550, PMCID: PMC9200401, DOI: 10.1200/po.21.00463.Peer-Reviewed Original ResearchASO Visual Abstract: Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, Nash C, Murray M, Richards P, Gittleman M, Budway R, Layeequr Rahman R, Kelemen P, Dooley W, Rock D, Cowan K, Lesnikoski B, Barone J, Ashikari A, Dupree B, Wang S, Menicucci A, Yoder E, Finn C, Corcoran K, Blumencranz L, Audeh W. ASO Visual Abstract: Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer. Annals Of Surgical Oncology 2022, 29: 4153-4154. DOI: 10.1245/s10434-022-11711-0.Peer-Reviewed Original ResearchAge-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, Nash C, Murray M, Richards P, Gittleman M, Budway R, Rahman R, Kelemen P, Dooley W, Rock D, Cowan K, Lesnikoski B, Barone J, Ashikari A, Dupree B, Wang S, Menicucci A, Yoder E, Finn C, Corcoran K, Blumencranz L, Audeh W. Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer. Annals Of Surgical Oncology 2022, 29: 4141-4152. PMID: 35378634, PMCID: PMC9174138, DOI: 10.1245/s10434-022-11666-2.Peer-Reviewed Original ResearchDoes Breast Cancer Subtype Impact Margin Status in Patients Undergoing Partial Mastectomy?
Horattas I, Fenton A, Gabra J, Mendiola A, Li F, Namm J, Solomon N, Gass J, Lum S, Murray M, Howard-McNatt M, Dupont E, Levine E, Brown E, Ollila D, Chiba A, Chagpar AB. Does Breast Cancer Subtype Impact Margin Status in Patients Undergoing Partial Mastectomy? The American Surgeon 2022, 88: 1607-1612. PMID: 34982015, DOI: 10.1177/00031348211069783.Peer-Reviewed Original Research